Mirikizumab Achieves Primary Endpoints in Phase 3a Trial for Crohn Disease
More than half of patients in the mirikizumab arm achieved clinical remission at week 52.
Source: hcplive.com
Stay updated with breaking news from Vivid 1. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
More than half of patients in the mirikizumab arm achieved clinical remission at week 52.